Brazil's largest domestically owned pharmaceutical company, owner of brands such as Neosaldina, Buscopan and Benegrip plus generics and branded generics, listed on B3 as HYPE3.
Last 90 days
Hypera began selling its Semavy semaglutide pen on September 4 at R$ 333, with a pledge to freeze the price, per Exame, g1 and CNN Brasil.
Updated October 28, 2026 · 3 verified articles
Market transmission
The stock tracks product launches and patent expiries, the annual CMED-regulated price adjustment, retail pharmacy inventories and leverage after acquisitions.
Explanatory mechanism, not a forecast or recommendation.Hypera posted net income of R$ 527 million in the third quarter of 2026, up 16.1% from a year earlier, with net revenue of R$ 2.44 billion and Ebitda of R$ 782.3 million, according to CNN Brasil and Money Times.
Anvisa barred Hypera from advertising Semavy, a prescription semaglutide pen. The ads were found on electronic panels at Congonhas airport, on the product website and on social media. Hypera says it is in talks with the agency and is already adjusting its communication.
Hypera began selling on September 4 its Semavy semaglutide pen at R$ 333 per pen in a three-unit kit, R$ 999 in total, per Exame, g1 and CNN Brasil. Per Exame, the company's chief executive said the price will stay frozen to retain customers; per CNN Brasil, a single pen costs R$ 464.80.